{"id":3145,"date":"2020-09-05T11:48:58","date_gmt":"2020-09-05T11:48:58","guid":{"rendered":"https:\/\/tansan.com.tr\/?page_id=3145"},"modified":"2020-09-05T12:29:02","modified_gmt":"2020-09-05T12:29:02","slug":"uz-dr-gulhan-ipek-deniz","status":"publish","type":"page","link":"https:\/\/tansan.com.tr\/en\/uz-dr-gulhan-ipek-deniz\/","title":{"rendered":"Specialist Dr. G\u00fclhan \u0130pek Deniz"},"content":{"rendered":"<p><strong>PERSONAL INFORMATION<\/strong><\/p>\n<ul>\n<li>Date of birth: May 19, 1983<\/li>\n<li>Foreign language skills: English<\/li>\n<\/ul>\n<p><strong>EDUCATION INFORMATION<\/strong><\/p>\n<ul>\n<li>Faculty of Medicine: Dicle University<\/li>\n<li>Internal Medicine: Istanbul Training and Research Hospital<\/li>\n<li>Medical Oncology Subspecialty: Istanbul University Cerrahpa\u015fa Faculty of Medicine<\/li>\n<\/ul>\n<p><strong>INFORMATION REGARDING WORK EXPERIENCE<\/strong><\/p>\n<ul>\n<li>Mardin Nusaybin Health Center No. 2, 2008-2008<\/li>\n<li>Istanbul Training and Research Hospital 2008-2013<\/li>\n<li>Gaziosmanpa\u015fa Taksim Training and Research Hospital 2013-2014<\/li>\n<li>Istanbul University, Cerrahpa\u015fa Faculty of Medicine (2014-2017)<\/li>\n<li>Mu\u015f State Hospital (2017-2017, Istanbul transfer due to spouse&#039;s employment)<\/li>\n<li>Istanbul \u015ei\u015fli Hamidiye Etfal Training and Research Hospital (2017-2020)<\/li>\n<li>Tansan Private Polyclinic 2020 \u2013 \u2026<\/li>\n<\/ul>\n<p><strong>GENERAL INFORMATION ABOUT CLINICAL RESEARCH<\/strong><\/p>\n<p><strong>ANNAR 42756493BLC3002<\/strong><\/p>\n<p>Biomarker Study to Identify Patients with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations<\/p>\n<p>Assistant researcher;<\/p>\n<p><strong>PDR00l<\/strong><\/p>\n<p>An open-label, multicenter Phase I\/II study on the safety and efficacy of PDR00 I administration in patients with advanced malignancies.<\/p>\n<p><strong>MON-7<\/strong><\/p>\n<p>A Phase III, randomized, double-blind, placebo-controlled study investigating tamoxifen and goserelin, or a nonsteroidal aromatase inhibitor (NSAID) and goserelin in combination with LEE011 or placebo, in the treatment of premenopausal women with Hannon receptor-positive, HER2-negative, advanced breast cancer.<\/p>\n<p><strong>Mon-2<\/strong><\/p>\n<p>A randomized, double-blind, placebo-controlled study of LEE011 in combination with letrozole for the treatment of postmenopausal women with advanced, hormone receptor-positive, HER2-negative breast cancer who have not previously received treatment for advanced disease.<\/p>\n<p><strong>MON-3<\/strong><\/p>\n<p>A randomized, double-blind, placebo-controlled study using ribociclib in combination with fulvestrant in men and postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who had not previously received treatment or had only received a series of endocrine therapies.<\/p>\n<p><strong>MCSllO<\/strong><\/p>\n<p>A randomized, phase II study using carboplatin and gemcitabine in combination with MCS10 in advanced stage triple-negative breast cancer (TNBC).<\/p>\n<p><strong>BOLER0-4<\/strong><\/p>\n<p>An open-label, single-arm, phase II study in which Everolimus is combined with Letrozol in the treatment of postmenopausal women with estrogen receptor-positive, HER2-negative, metastatic or locally advanced breast cancer.<\/p>\n<p><strong>BOLER0-6<\/strong><\/p>\n<p>A three-arm, randomized, open-label phase II study comparing everolimus or capecitabine in combination with exemestane in postmenopausal women with estrogen receptor-positive, locally advanced, recurrent, or metastatic breast cancer following recurrence or progression after previous administration of letrozole or anastrozol.<\/p>\n<p><strong>I3Y-MC-JPBM<\/strong><\/p>\n<p>A placebo-controlled, randomized, double-blind, phase 3 study comparing nonsteroidal aromatase inhibitors (Anastrozole or Letrozole) in combination with a CDK4\/6 inhibitor, L Y2835219, or placebo in hormone receptor-positive, HER2-negative, postmenopausal women with locally recurrent or metastatic breast cancer who had not previously received systemic treatment.<\/p>\n<p><strong>I3Y-MC-JPBK JUNIPER<\/strong><\/p>\n<p>A randomized, phase 3 study comparing abemaciclib and best supportive treatment with erlotinib and best supportive treatment in stage IV non-small cell lung cancer patients with KRAS mutations who experienced progression after platinum-based chemotherapy.<\/p>\n<p><strong>14T-MC-JVDC<\/strong><\/p>\n<p>A placebo-controlled, randomized, double-blind, phase 3 study comparing ramusirumab with docetaxel and placebo with docetaxel in patients with locally advanced, surgically unresectable, or metastatic urothelial cell carcinoma who experienced progression during or after platinum-based therapy.<\/p>\n<p><strong>14D-MC-JTJH<\/strong><\/p>\n<p>A Phase 2 study using LY2606368 in patients with advanced-stage small cell lung cancer.<\/p>\n<p><strong>13Y-MC-JPCE<\/strong><\/p>\n<p>A Phase 2 Study Combining Abemaciclib with Pembrolizumab in Patients with Stage IV Non-Small Cell Lung Cancer or Hormone Receptor Positive, HER2 Negative Breast Cancer.<\/p>\n<p><strong>130-MC-JSBF<\/strong><\/p>\n<p>A randomized, double-blind, phase 2 study in which cisplatin and gemcitabine are used in combination with ramusirumab, merestinib, or placebo as first-line therapy in patients with advanced or metastatic biliary tract cancer.<\/p>\n<p><strong>I4T-MC-JVCZ<\/strong><\/p>\n<p>A randomized, phase 2 study evaluating alternative ramusirumab doses in combination with paclitaxel in stage 2 metastatic or locally advanced, unresectable gastric or gastroesophageal junction adenocarcinoma.<\/p>\n<p><strong>lmvigor130<\/strong><\/p>\n<p>A phase 3, multicenter, randomized, placebo-controlled, double-blind study comparing the combination of atezolizumab (anti-PD-L1 antibody) with gemcitabine\/carboplatin to gemcitabine\/carboplatin alone in patients with untreated locally advanced or metastatic urothelial carcinoma unsuitable for cisplatin-based chemotherapy.<\/p>\n<p><strong>IMvigor010<\/strong><\/p>\n<p>- A Phase 1, Open-Label, Multicenter, Randomized Study of Observation vs. Adjuvant Therapy in Patients with PD-L-1 Selective, High-Risk Muscle Invasive Bladder Cancer Following Cystectomy with MPDL3280A (Anti-PD-L-1 Antibody).<\/p>\n<p><strong>aPDL 1 Basket<\/strong><\/p>\n<p>- An open-label, multi-cohort, phase-1 study of MPDL3280A in advanced solid tumors.<\/p>\n<p><strong>SANDPIPER<\/strong><\/p>\n<p>- A Phase 11, double-blind, placebo-controlled, randomized study comparing taselisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with estrogen receptor-positive and HER2-negative locally advanced or metastatic breast cancer who experienced disease relapse or progression during or after aromatase inhibitor therapy.<\/p>\n<p><strong>RCC<\/strong><\/p>\n<p>Sunitinib versus Bevacizumab in combination with MPDL328\u03b1 (Anti-PD-L1 Antibody) in patients with untreated advanced renal cell carcinoma.<\/p>\n<p>Evaluator<\/p>\n<p>Phase 111 is an open-label, randomized trial.<\/p>\n<p><strong>IMvigor211<\/strong><\/p>\n<p>A phase 111, open-label, multicenter, randomized trial investigating the efficacy and safety of MPDL3280A (anti-PD-L1 antibody) compared to chemotherapy after failure of platinum-containing chemotherapy in patients with locally advanced or metastatic urothelial bladder cancer. .<\/p>\n<p><strong>JACOB<\/strong><\/p>\n<p>A double-blind, placebo-controlled, randomized, multicenter Phase 111 study evaluating the efficacy and safety of pertuzumab in combination with trastuzumab and chemotherapy in patients with HER2-positive metastatic gastroesophageal junction and gastric cancer.<\/p>\n<p><strong>UMBRELLA ML28851<\/strong><\/p>\n<p>AN OPEN-LABEL, MULTINATIONAL, MULTICENTREPRENEURIAL, PHASE 111 STUDY EVALUATING PATIENT SATISFACTION WITH SUBCUTANEOUS TARSTUZUMAB ADMINISTRATION IN HER2-POSITIVE EARLY-STAGE BREAST CANCER PATIENTS. .<\/p>\n<p><strong>KAMILLA MO28231<\/strong><\/p>\n<p>A multicenter, single-arm study of trastuzumab emtansine (T-DM1) in patients with locally advanced or metastatic breast cancer who have previously received anti-HER2 and chemotherapy-based treatment and are HER2-positive.<\/p>\n<p><strong>JAVELIN200<\/strong><\/p>\n<p>\u201cA Phase 111, open-label, multicenter study evaluating avelumab (MSB0010718C) versus docetaxel in patients with non-small cell lung cancer who experienced disease progression after platinum-containing dual therapy.\u201d<\/p>\n<p><strong>impower110<\/strong><\/p>\n<p>A phase 111, open-label, randomized trial evaluating MPDL3280A (anti-PDL-1 antibody) against cisplatin or carboplatin + pemetrexed in selected, unchemotherapyd stage 4 non-squamous cell non-small cell lung cancer patients for PDL-1.<\/p>\n<p><strong>MK 3475 -061<\/strong><\/p>\n<p>Phase 111 Randomized Study Comparing Pembrolizumab (MK-3475) with Paclitaxel in Volunteers with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Experiencing Progression After First-Line Therapy with Platinum and Fluoropyrimidine,<\/p>\n<p>Open-label clinical trial.<\/p>\n<p><strong>KEYNOTE-361<\/strong><\/p>\n<p>Phase 111 Randomized, Controlled Study Evaluating Pembrolizumab Alone or in Combination with Chemotherapy in Advanced Urothelial Carcinoma<\/p>\n<p><strong>MK 3475 -355<\/strong><\/p>\n<p>A randomized, double-blind, phase 111 study comparing pembrolizumab (MK-3475) plus chemotherapy combination to placebo plus chemotherapy in previously untreated volunteers with inoperable locally advanced or metastatic triple-negative breast cancer.<\/p>\n<p><strong>MDV3100-14<\/strong><\/p>\n<p>Phase 1 study of Pembrolizumab (MK3475) in volunteers with castration-resistant metastatic prostate cancer (mCRPC) who have previously received chemotherapy.<\/p>\n<p><strong>PROSPER<\/strong><\/p>\n<p>Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Enzalutamide in Patients with Non-Metastatic Castration-Resistant Prostate Cancer.<\/p>\n<p><strong>Other<\/strong><\/p>\n<p>Betul Borku Uysal, Feray AUkbas, Esma Altunoglu, Gulhan ipek Deniz, Duygu Uysal, Harun Uysal, Hanife Usta Atmaca, Yasin Yuksel, Hale Aral, Guven Cetin; M. Cem Ar, Mustafa Boz, Fusun Erdenen, The Effect Of Serum Hepcidin Level On Anemia In Heart Failure,<\/p>\n<p>The Korean Journal of Internal Medicine Yol. 29, No. 5 (Suppl. 1), PS 0070, WCIM 2014.<\/p>\n<p>1-Ya\u011fbasan Ye\u015filada Belma, \u0130pek Deniz G\u00fclhan, Ar Muhlis Cem, \u00c7etin G\u00fcven, Huq G\u00fcl ben, Sameto\u011flu Fettah (2013). Simple Prognostic Factors in Non-Hodgkin Lymphoma.<\/p>\n<p>39th National Heniatology Congress, (Control No: 679731). .<\/p>\n<p>2-Ahmet Baran, G\u00fclhan \u0130pek Deniz, Sibel \u00c7etin Erdamar, Nuray Kepil, Muharrem K\u00f6se, Hande Turna, \u00c7i\u011fdem Papila, Fuat Demirelli (2015).<\/p>\n<p>A Case of Lung Cancer Diagnosed by Colonoscopy. 21st National Cancer Congress (PO 18).<\/p>\n<p>3- G\u00fclhan \u0130pek Deniz, Atakan Demir, Bilge \u00d6z, Serg\u00fclen Dervi\u015fo\u011flu, Nil \u00c7omuno\u011flu, Emire Seyahi Kural, Y\u0131ld\u0131z \u015eeng\u00fcl, Hande Turna, \u00c7i\u011fdem Papila, Fuat Demirelli (2015).<\/p>\n<p>Malignant Mesothelioma Cases Developing on the Background of Familial Mediterranean Fever.<\/p>\n<p>21st National Cancer Congress (P062).<\/p>\n<p>4-G\u00fclhan \u0130pek Deniz, \u015ee\u0131min G\u00fcven Me\u015fe, Zerrin Calay, Sinem Ko\u00e7ak, Ahmet Baran, Hande Turna, \u00c7i\u011fdem Papila, Fuat Demirelli (2015). A Rare Case: Primary Neuroendocrine Breast Carcinoma.<\/p>\n<p>21st National Cancer Congress (P223).<\/p>\n<p>5-Sinem Ko\u00e7ak, G\u00fclhan \u0130pek Deniz, C\u00fcyan Demirkesen, Serg\u00fclen Dervi\u015fo\u011flu, Hande Turna, Mustafa \u00d6zg\u00fcro\u011flu (2015).<\/p>\n<p>Metastatic Kapossi Sarcoma in an Immunosuppressive Background: Two Cases<\/p>\n<p>21st National Cancer Congress (P138).<\/p>\n<p>6- Atakan Demir, Ahmet Baran, Gizem Ayan, \u00d6zcan Y\u0131ld\u0131z, Mesut Y\u0131lmaz, \u015eermin G\u00fcven Me\u015fe, Sinem Ko\u00e7ak, G\u00fclhan \u0130pek Deniz, Hande Turna, Mustafa \u00d6zg\u00fcro\u011flu, Fuat Hulusi Demirelli<\/p>\n<p>THE EFFECTIVENESS OF SYSTEMIC TREATMENTS IN THYROID CANCERS RESTRUCTURAL TO RADIOACTIVE IODINE THERAPY.<\/p>\n<p>21st National Cancer Congress (P321).<\/p>\n<p>7- Ali Can, \u015eermin G\u00fcven Me\u015fe, Atakan Demir, G\u00fclhan \u0130pek Deniz, Mesut Y\u0131lmaz, Ahmet Baran, Sinem Ko\u00e7ak, Z. Hande Turna, \u00c7i\u011fdem Papila, Fuat H. Demirelli. .<\/p>\n<p>NEUROENDOCRINE TUMORS: 10 YEARS OF EXPERIENCE IN A SINGLE CENTER.<\/p>\n<p>21st National Cancer Congress (P370).<\/p>\n<p>8- \u015eermin G\u00fcven Me\u015fe, Ali Can, Atakan Demir, Teoman Yanmaz, G\u00fclhan \u0130pek Deniz, Mesut Y\u0131lmaz, Sinem Ko\u00e7ak, Ahmet Baran, Z. Hande Turna, Mustafa \u00d6zg\u00fcro\u011flu<\/p>\n<p>Efficacy of Bevacizumab in Recurrent Epithelial Ovarian Cancer.<\/p>\n<p>21st National Cancer Congress (P406).<\/p>\n<p>9- G\u00fclhan \u0130pek Deniz, Sinem Ko\u00e7ak, \u015eermin G\u00fcven Me\u015fe, Mesut Y\u0131lmaz, Ahmet Baran, Atakan Demir, Hande Turna, \u00c7i\u011fdem Papila, Fuat Demirelli<\/p>\n<p>Efficacy and Tolerability of Sorafenib in Patients with Hepatocellular Carcinoma<\/p>\n<p>21st National Cancer Congress (P534).<\/p>\n<p>10- Sinem Ko\u00e7ak, G\u00fclhan \u0130pek Deniz, \u015eermin G\u00fcven Me\u015fe, Ahmet Baran, Mesut Y\u0131lmaz, Atakan Demir, Hande Turna, Nil Molinas Mandel, \u00c7i\u011fdem Papila, Fuat Demirelli<\/p>\n<p>EFFICACY AND SAFETY OF PAZOPANIB IN SOFT TISSUE SARCOMAS.<\/p>\n<p>21st National Cancer Congress (P408).<\/p>\n<p>11- G\u00fclhan \u0130pek Deniz, \u015eermin G\u00fcven Me\u015fe, Atakan Demir, Mesut Y\u0131lmaz, Ahmet Baran, Sinem Ko\u00e7ak, Hande Turna, Fuat Demirelli.(2014)<\/p>\n<p>HOW AGGRESSIVE CAN BASAL CELL CARCINOMA BE?<\/p>\n<p>1st Geriatric Oncology Congress (P005 l).<\/p>\n<p>12-S-004 NATIONAL LUNG CANCER CONGRESS 2020<\/p>\n<p>THE ROLE OF PET\/CT IN TARGETED THERAPIES IN LUNG CANCER<\/p>\n<p>Re\u015fit Akyel 1, Emre Demirci 2, G\u00fclhan \u0130pek Deniz 1, 1 \u015ei\u015fli Hamidiye Etfal EAH 2 TC Yeditepe University Ko\u015fuyolu Hospital<\/p>\n<p>13-S-009 NATIONAL LUNG CANCER CONGRESS 2020<\/p>\n<p>NON-SMALL CELL LUNG CANCER AND TYROSINE KINASE INHIBITORS<\/p>\n<p>G\u00fclhan \u0130pek Deniz l , 1 \u015ei\u015fli Hamidiye Etfal EAH<\/p>\n<p>14-Abstract P5-11-19: Ribociclib for the treatment of hormone receptor-positive refractory advanced breast cancer: Managed access program in Turkey<\/p>\n<p>Umut Demirci, Erhan Gokmen, Yesim Eralp, Seyda Gunduz, Sema Sezgin Goksu, Taner Korkmaz, Osman Kostek, Serdar Turhal, Semra Paydas, Sevgi Topcu, Burcu Cakar, Bulent Karabulut, Ozgur Tanr\u0131verdi, Burcak Karaca, Gulhan Ipek Deniz, Ozkan Alan, Fatma Paksoy Turkoz and Gul Basaran<\/p>\n<p>DOi: 10.1158\/1538-7445.SABCS19-P5-11-19 Published February 2020<\/p>\n<p><strong>Book and Magazine Authorship<\/strong><\/p>\n<p>1- Adjuvant Treatment in Gastric Cancer, CANCER AGENDA Volume: 3\/1, March 2015.<\/p>\n<p>T\u00fcrkiye FIGHT AGAINST CANCER FOUNDATION, Dr. G\u00fclhan \u0130pek Deniz, Istanbul University Cerrahpa\u015fa Faculty of Medicine, Department of Medical Oncology<\/p>\n<p>2. Current Approaches in Surgical and Systemic Treatment of Abdominal Sarcoma<\/p>\n<p>Chapter 11, Systemic Treatment of Desmoid Tumors, G\u00fclhan \u0130PEK DEN\u0130Z<\/p>\n<p>3- Approach to Gastrointestinal Stromal Tumors and Neuroendocrine Tumors<\/p>\n<p>Chapter 25, Neuroendocrine Tumor Metastases and Systemic Treatment, G\u00fclhan \u0130PEK DEN\u0130Z<\/p>\n<p><strong>Speaker<\/strong><\/p>\n<p>INNOVATIONS IN NON-MELANOMA SKIN CANCERS G\u00fclhan \u0130pek Deniz \u015ei\u015fli Hamidiye Etfal Training and Research Hospital, Medical Oncology, Istanbul<\/p>\n<p>3rd CONGRESS ON YOUNG PEOPLE&#039;S PERSPECTIVES ON ONCOLOGY 2020<\/p>","protected":false},"excerpt":{"rendered":"<p>PERSONAL INFORMATION Date of birth: May 19, 1983 Foreign language skills: English EDUCATION Medical Faculty: Dicle University Internal Medicine: Istanbul Training and Research Hospital Medical Oncology Subspecialty: Istanbul University Cerrahpa\u015fa Faculty of Medicine WORK EXPERIENCE Mardin Nusaybin No. 2 Health Center 2008-2008 Istanbul Training and Research Hospital 2008-2013 Gaziosmanpa\u015fa Taksim Training and Research Hospital 2013-2014<\/p>","protected":false},"author":3,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-3145","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Uz. Dr. G\u00fclhan \u0130pek Deniz - \u00d6zel Tansan Poliklini\u011fi<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tansan.com.tr\/en\/uz-dr-gulhan-ipek-deniz\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Uz. Dr. G\u00fclhan \u0130pek Deniz - \u00d6zel Tansan Poliklini\u011fi\" \/>\n<meta property=\"og:description\" content=\"K\u0130\u015e\u0130SEL B\u0130LG\u0130LER Do\u011fum tarihi: 19.05.1983 Yabanc\u0131 dil bilgisi: \u0130ngilizce E\u011e\u0130T\u0130M B\u0130LG\u0130LER\u0130 T\u0131p Fak\u00fcltesi: Dicle \u00dcniversitesi \u0130\u00e7 Hastal\u0131klar\u0131: \u0130stanbul E\u011fitim Ve Ara\u015ft\u0131rma Hastanesi T\u0131bb\u0131 Onkoloji Yan Dal: \u0130stanbul \u00dcniversitesi Cerrahpa\u015fa T\u0131p Fak\u00fcltesi \u0130\u015e TECR\u00dcBES\u0130NE A\u0130T B\u0130LG\u0130LER Mardin Nusaybin 2 nolu Sa\u011fl\u0131k Oca\u011f\u0131 2008-2008 \u0130stanbul E\u011fitim ve Ara\u015ft\u0131rma Hastanesi 2008-2013 Gaziosmanpa\u015fa Taksim E\u011fitim Ve Ara\u015ft\u0131rma Hastanesi 2013-2014\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tansan.com.tr\/en\/uz-dr-gulhan-ipek-deniz\/\" \/>\n<meta property=\"og:site_name\" content=\"\u00d6zel Tansan Poliklini\u011fi\" \/>\n<meta property=\"article:modified_time\" content=\"2020-09-05T12:29:02+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/tansan.com.tr\/uz-dr-gulhan-ipek-deniz\/\",\"url\":\"https:\/\/tansan.com.tr\/uz-dr-gulhan-ipek-deniz\/\",\"name\":\"Uz. Dr. G\u00fclhan \u0130pek Deniz - \u00d6zel Tansan Poliklini\u011fi\",\"isPartOf\":{\"@id\":\"https:\/\/tansan.com.tr\/#website\"},\"datePublished\":\"2020-09-05T11:48:58+00:00\",\"dateModified\":\"2020-09-05T12:29:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/tansan.com.tr\/uz-dr-gulhan-ipek-deniz\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/tansan.com.tr\/uz-dr-gulhan-ipek-deniz\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/tansan.com.tr\/uz-dr-gulhan-ipek-deniz\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Ana sayfa\",\"item\":\"https:\/\/tansan.com.tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Uz. Dr. G\u00fclhan \u0130pek Deniz\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/tansan.com.tr\/#website\",\"url\":\"https:\/\/tansan.com.tr\/\",\"name\":\"Tansan Onkoloji - \u00d6zel Tansan Poliklini\u011fi\",\"description\":\"Kanser Te\u015fhis ve Tedavisi\",\"publisher\":{\"@id\":\"https:\/\/tansan.com.tr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/tansan.com.tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/tansan.com.tr\/#organization\",\"name\":\"\u00d6zel Tansan Onkoloji Poliklini\u011fi\",\"url\":\"https:\/\/tansan.com.tr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/tansan.com.tr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/tansan.com.tr\/wp-content\/uploads\/2020\/02\/TansanLogo-1.png\",\"contentUrl\":\"https:\/\/tansan.com.tr\/wp-content\/uploads\/2020\/02\/TansanLogo-1.png\",\"width\":274,\"height\":66,\"caption\":\"\u00d6zel Tansan Onkoloji Poliklini\u011fi\"},\"image\":{\"@id\":\"https:\/\/tansan.com.tr\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Uz. Dr. G\u00fclhan \u0130pek Deniz - \u00d6zel Tansan Poliklini\u011fi","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tansan.com.tr\/en\/uz-dr-gulhan-ipek-deniz\/","og_locale":"en_GB","og_type":"article","og_title":"Uz. Dr. G\u00fclhan \u0130pek Deniz - \u00d6zel Tansan Poliklini\u011fi","og_description":"K\u0130\u015e\u0130SEL B\u0130LG\u0130LER Do\u011fum tarihi: 19.05.1983 Yabanc\u0131 dil bilgisi: \u0130ngilizce E\u011e\u0130T\u0130M B\u0130LG\u0130LER\u0130 T\u0131p Fak\u00fcltesi: Dicle \u00dcniversitesi \u0130\u00e7 Hastal\u0131klar\u0131: \u0130stanbul E\u011fitim Ve Ara\u015ft\u0131rma Hastanesi T\u0131bb\u0131 Onkoloji Yan Dal: \u0130stanbul \u00dcniversitesi Cerrahpa\u015fa T\u0131p Fak\u00fcltesi \u0130\u015e TECR\u00dcBES\u0130NE A\u0130T B\u0130LG\u0130LER Mardin Nusaybin 2 nolu Sa\u011fl\u0131k Oca\u011f\u0131 2008-2008 \u0130stanbul E\u011fitim ve Ara\u015ft\u0131rma Hastanesi 2008-2013 Gaziosmanpa\u015fa Taksim E\u011fitim Ve Ara\u015ft\u0131rma Hastanesi 2013-2014","og_url":"https:\/\/tansan.com.tr\/en\/uz-dr-gulhan-ipek-deniz\/","og_site_name":"\u00d6zel Tansan Poliklini\u011fi","article_modified_time":"2020-09-05T12:29:02+00:00","twitter_card":"summary_large_image","twitter_misc":{"Estimated reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/tansan.com.tr\/uz-dr-gulhan-ipek-deniz\/","url":"https:\/\/tansan.com.tr\/uz-dr-gulhan-ipek-deniz\/","name":"Uz. Dr. G\u00fclhan \u0130pek Deniz - \u00d6zel Tansan Poliklini\u011fi","isPartOf":{"@id":"https:\/\/tansan.com.tr\/#website"},"datePublished":"2020-09-05T11:48:58+00:00","dateModified":"2020-09-05T12:29:02+00:00","breadcrumb":{"@id":"https:\/\/tansan.com.tr\/uz-dr-gulhan-ipek-deniz\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tansan.com.tr\/uz-dr-gulhan-ipek-deniz\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/tansan.com.tr\/uz-dr-gulhan-ipek-deniz\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Ana sayfa","item":"https:\/\/tansan.com.tr\/"},{"@type":"ListItem","position":2,"name":"Uz. Dr. G\u00fclhan \u0130pek Deniz"}]},{"@type":"WebSite","@id":"https:\/\/tansan.com.tr\/#website","url":"https:\/\/tansan.com.tr\/","name":"Tansan Onkoloji - \u00d6zel Tansan Poliklini\u011fi","description":"Cancer Diagnosis and Treatment","publisher":{"@id":"https:\/\/tansan.com.tr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tansan.com.tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/tansan.com.tr\/#organization","name":"\u00d6zel Tansan Onkoloji Poliklini\u011fi","url":"https:\/\/tansan.com.tr\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/tansan.com.tr\/#\/schema\/logo\/image\/","url":"https:\/\/tansan.com.tr\/wp-content\/uploads\/2020\/02\/TansanLogo-1.png","contentUrl":"https:\/\/tansan.com.tr\/wp-content\/uploads\/2020\/02\/TansanLogo-1.png","width":274,"height":66,"caption":"\u00d6zel Tansan Onkoloji Poliklini\u011fi"},"image":{"@id":"https:\/\/tansan.com.tr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/tansan.com.tr\/en\/wp-json\/wp\/v2\/pages\/3145","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tansan.com.tr\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/tansan.com.tr\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/tansan.com.tr\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/tansan.com.tr\/en\/wp-json\/wp\/v2\/comments?post=3145"}],"version-history":[{"count":8,"href":"https:\/\/tansan.com.tr\/en\/wp-json\/wp\/v2\/pages\/3145\/revisions"}],"predecessor-version":[{"id":3156,"href":"https:\/\/tansan.com.tr\/en\/wp-json\/wp\/v2\/pages\/3145\/revisions\/3156"}],"wp:attachment":[{"href":"https:\/\/tansan.com.tr\/en\/wp-json\/wp\/v2\/media?parent=3145"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}